




The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 192% points. The greatest weakness of Filana Therapeutics INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 400%, being 186% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	136,532
Cost of Goods Sold	0
Intangible Assets	37
Liabilities, Current	11,750
Liabilities, Non-Current	79
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-108,183
Other Liabilities	0
Other Net Income	8,921
Other Revenues	0
Property and Equipment	20,964
Research and Development	69,637
Selling, General and Administrative Expense	71,809

Output Variable	Value in 1000 USD
Assets	157,533
Liabilities	11,829
Expenses	33,263
Revenues	0
Stockholders Equity	145,704
Net Income	-24,342
Comprehensive Net Income	-24,342
BaseVar	105,773
ECR before LimitedLiability	346%
Economic Capital Ratio	400%